JP2014530249A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530249A5
JP2014530249A5 JP2014536344A JP2014536344A JP2014530249A5 JP 2014530249 A5 JP2014530249 A5 JP 2014530249A5 JP 2014536344 A JP2014536344 A JP 2014536344A JP 2014536344 A JP2014536344 A JP 2014536344A JP 2014530249 A5 JP2014530249 A5 JP 2014530249A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
use according
ibs
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014536344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530249A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014530249A publication Critical patent/JP2014530249A/ja
Publication of JP2014530249A5 publication Critical patent/JP2014530249A5/ja
Pending legal-status Critical Current

Links

JP2014536344A 2011-10-18 2012-10-10 ネツピタントおよびパロノセトロンの治療学的組合せ Pending JP2014530249A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161548514P 2011-10-18 2011-10-18
US61/548,514 2011-10-18

Publications (2)

Publication Number Publication Date
JP2014530249A JP2014530249A (ja) 2014-11-17
JP2014530249A5 true JP2014530249A5 (https=) 2015-11-19

Family

ID=47178220

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014536344A Pending JP2014530249A (ja) 2011-10-18 2012-10-10 ネツピタントおよびパロノセトロンの治療学的組合せ

Country Status (11)

Country Link
US (1) US9358228B2 (https=)
EP (2) EP2759298B1 (https=)
JP (1) JP2014530249A (https=)
CN (3) CN106974912A (https=)
DK (1) DK2744497T3 (https=)
ES (1) ES2579616T3 (https=)
HK (1) HK1198121A1 (https=)
HU (1) HUE030811T2 (https=)
PL (1) PL2744497T3 (https=)
PT (1) PT2744497T (https=)
WO (1) WO2013057554A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3435980T (pt) * 2016-06-06 2020-02-21 Helsinn Healthcare Sa Formulações injetáveis fisiologicamente equilibradas de fosnetupitant
CN108721214B (zh) * 2017-04-14 2020-06-16 和龙 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
TW202428273A (zh) 2023-01-03 2024-07-16 瑞士商赫爾辛保健公司 奈妥吡坦(netupitant)及帕洛諾司瓊(palonosetron)的液態口服調配物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL166272B1 (pl) 1989-11-28 1995-04-28 Syntex Inc Sposób wytwarzania nowych addycyjnych soli z kwasami zwiazków trójpierscieniowych PL PL PL PL
US5510486A (en) 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
ES2327600T3 (es) * 1999-02-18 2009-11-02 Novasearch Ag Uso de antagonistas del receptor de la 5-ht3 para el tratamiento de enfermedades musculoesqueleticas.
EP1394150B1 (en) 1999-02-24 2011-01-19 F. Hoffmann-La Roche AG 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
PT1303490E (pt) 2000-07-14 2008-09-04 Hoffmann La Roche Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina
MXPA03005169A (es) 2000-12-14 2003-09-22 Hoffmann La Roche Matriz lipidica auto-emulsificante.
MXPA05007381A (es) * 2003-01-13 2006-02-10 Dynogen Pharmaceuticals Inc Metodo para el tratamiento de transtornos funcionales del intestino.
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
JO2676B1 (en) * 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
JP2008505107A (ja) 2004-07-01 2008-02-21 シェーリング コーポレイション Nk1アンタゴニストとしてのピペリジン誘導体
WO2007128056A1 (en) * 2006-05-03 2007-11-15 Cnsbio Pty Ltd Methods and composition for treatment of inflammatory pain
CN101573106B (zh) 2006-10-24 2013-07-24 赫尔辛医疗股份公司 具有改进的稳定性和生物利用度的含帕洛司琼盐酸盐的软胶囊剂
US20100316678A1 (en) 2007-06-28 2010-12-16 Cnsbio Pty Ltd. Combination methods and compositions for treatment of neuropathic pain
PT2722045T (pt) * 2009-11-18 2016-10-18 Helsinn Healthcare Sa Composições para o tratamento de náuseas e vómitos mediadas centralmente

Similar Documents

Publication Publication Date Title
JP5399898B2 (ja) 神経因性疼痛の治療用カンナビノイド
JP2023171776A (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
CN104968368A (zh) 固溶体组合物及其在剧痛中的用途
JP2017510607A5 (https=)
JP2017132791A (ja) 組み合わせ組成物
AU2022202218A1 (en) Combination Therapy Using Acamprosate And D-Cycloserine
CA2735834C (en) Composition comprising ibuprofen and paracetamol to treat pain caused by osteoarthritis and rheumatoid arthritis
JP2016505050A5 (https=)
HRP20240812T1 (hr) Oblici doziranja i terapijska primjena l-4-klorokinurenina
JP2014530249A5 (https=)
FI4255563T3 (fi) 5’-o-fenyyliasetyyliuridiini ja terapeuttinen käyttö
JP2014530249A (ja) ネツピタントおよびパロノセトロンの治療学的組合せ
JP2020527156A5 (https=)
CN115835862A (zh) 治疗阿尔茨海默病的组合及其应用
WO2022037006A1 (zh) 一种止痛止痒药物组合物及其应用方法
CN104117065B (zh) 一种基于青藤碱的用于镇痛的药物组合产品
JP2013126971A (ja) 抗感冒剤
CN110279691A (zh) 一种外科术后护理镇痛药物及其用途
UA112652C2 (uk) Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції
RU2023116805A (ru) 5'-o-фенилацетилуридин и терапевтическое применение
CN117243948A (zh) 包含瑞香素的组合物在制备风湿性关节炎药物中的应用
JPWO2009025091A1 (ja) 線維筋痛症治療用医薬組成物
JP2022541634A (ja) 疼痛に関連する睡眠障害を治療する方法
Peterson Postherpetic neuralgia in the elderly: Debilitating and difficult to manage
KR20200088861A (ko) 우울증의 예방 또는 치료용 벤조익산 또는 이의 염 및 유도체